| Company/Division name | AstraZeneca |
| Parent company | Astra Zeneca |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2025 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 50,000 |
| Country(ies) from which reshored: | United Kingdom |
| State(s) reshored to: | VA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Pharmaceuticals |
| What non-domestic negative factors made offshoring less attractive? | Tariffs |
| What domestic positive factors made reshoring more attractive? | Automation/technology, Eco-system synergies, Image/brand, Manufacturing/engineering joint innovation (R&D), Proximity to customers/market, Skilled workforce availability/training |
